Specific activation of apoptosis in tumor cells offers a promising approach for cancer therapy. Induction of apoptosis leads to activation of specific proteases. Two major pathways for caspase activation in mammalian cells have been described. One apoptotic pathway involves members of the tumor necrosis factor family of cytokine receptors (eg death receptor 5 (DR5)). The other pathway is controlled by the Bcl-2 family of proteins. The purpose of this study was to investigate whether increased apoptosis occurs in human glioma cells following infection with a recombinant adenoviral vector encoding the human Bax gene under the control of human vascular endothelial growth factor (VEGF) promoter element (AdVEGFBax) in combination with an anti-human DR5 monoclonal antibody (TRA-8). Specific overexpression of exogenous Bax protein induced apoptosis and cell death in glioma cell lines, through activation of both caspase-8 and -9, leading to activation of downstream caspase-3. The relative sensitivity to AdVEGFBax for the glioma cell lines was U251MG4U373MG4U87MG4D54MG. The recently characterized TRA-8 monoclonal antibody induces apoptosis of most TRAIL-sensitive tumor cells by specific binding to DR5 receptors on the cellular membrane. TRA-8 induced rapid apoptosis and cell death in glioma cells, but did not demonstrate detectable cytotoxicity of primary normal human astrocytes. The efficiency of TRA-8-induced apoptosis was variable in different glioma cell lines. The relative sensitivity to TRA-8 was U373MG4U87MG4U251MG4D54MG. The combination of TRA-8 treatment and overexpression of Bax overcame TRA-8 resistance of glioma cells in vitro. Cell viability of U251MG cells was 71.1% for TRA-8 (100 ng/ml) alone, 75.9% for AdVEGFBax (5 MOI) alone and 41.1% for their combination as measured by MTS assay. Similar enhanced apoptosis results were obtained for the other glioma cell lines. In vivo studies demonstrated that the combined treatment significantly (Po0.05) suppressed the growth of U251MG xenografts and produced 60% complete tumor regressions without recurrence. These data suggest that the combination of TRA-8 treatment with specific overexpression of Bax using AdVEGFBax may be an effective approach for the treatment of human malignant gliomas.
Introduction
Programmed cell death (apoptosis) plays critical roles in a wide variety of physiological processes. Deregulation of the balance between cell proliferation and death contributes to many diseases, including cancer. Specific activation of apoptosis in tumor cells may provide a promising approach for cancer therapy. Numerous proteins that control apoptosis in cancer cells have been identified. Induction of apoptosis involves a cascade of consecutive biochemical events that leads to activation of specific proteases, which are present in inactive proforms, but can be triggered to assume an active state of caspases after cleavage. 1 Two of the major pathways for caspase activation in mammalian cells were described in detail. The extrinsic pathway can be induced by members of the tumor necrosis factor family of cytokine receptors. These proteins recruit adapter proteins to their cytosolic death domains, which then bind death effector domaincontaining procaspases, particularly procaspase-8. The other (intrinsic) apoptotic pathway can be induced by release of cytochrome c from mitochondria, through elevations in the levels of pore-forming proapoptotic Bcl-2 family proteins such as Bax. Translocation of Bax homodimer to the mitochondria can trigger release of cytochrome c and activate the caspase pathway causing apoptotic death of mammalian cells. 2 In the cytosol, cytochrome c binds and activates Apaf-1, allowing it to bind and activate procaspase-9. Active caspase-9 and caspase-8 have been shown to directly cleave and activate the effector protease caspase-3. 1 The anticancer effects of Bax gene overexpression have been investigated using a strategy that employs adenoviral vectors for high-efficiency gene transfer into mammalian cells. Several binary adenoviral recombinant systems for Bax gene expression have been generated. 3, 4 However, the requirement for cells to be infected with two adenoviruses can restrict the clinical potential for this approach. To overcome this limitation, we have utilized a single adenoviral vector encoding the Bax protein under the control of vascular endothelial growth factor (VEGF) promoter element.
Several members of the tumor necrosis factor superfamily of cytokine receptors, such as the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), can trigger caspase activation and result in rapid apoptosis through binding of specific proapoptotic receptors, DR4 (TRAIL-R1) and DR5 (TRAIL-R2). Ligand-induced activation of receptor signals through the intracellular death domain protein FADD (Fas-associated death domain protein) involves the caspase-8-dependent pathway. 5 Soluble human TRAIL can induce apoptosis in a wide variety of cancer cell lines without significant effects on normal cells in vitro. 6, 7 On the other hand, the ability of TRAIL to induce hepatocellular toxicity can limit the tumoricidal potential for this therapy in vivo. In addition, TRAIL has a very short half-life in circulation. A novel anti-human DR5 monoclonal antibody, TRA-8, is able to overcome these restrictions. 8 The purpose of this study was to investigate whether increased apoptosis and cell death occur in human glioma cells in vitro and in vivo following infection with a recombinant adenoviral vector encoding the human Bax gene under the control of human VEGF promoter element in combination with an anti-human DR5 monoclonal antibody, TRA-8.
Materials and methods

Cell cultures, antibodies and adenoviral vectors
Established human glioma cell lines D54MG, U87MG, U251MG, U373MG and normal human primary astrocytes were obtained from G Yancey Gillespie (University of Alabama at Birmingham, Birmingham, AL, USA) and maintained in Dulbecco's modified Eagle's minimum essential medium (DMEM) (Mediatech, Herndon, VA, USA) with 10% fetal bovine serum (FBS) (Summit Biotechnology, Fort Collins, CO, USA). The human embryonic kidney 293 cells (Microbix Biosystems Inc., Ontario, Canada) were grown in DMEM/F12 (Mediatech) medium with 10% FBS. All the cells were maintained at 371C in a humidified atmosphere with 5% CO 2 .
An anti-human DR5 mouse monoclonal antibody, TRA-8, was provided by Sankyo Co., Ltd (Tokyo, Japan). Anti-caspase-8, -9 and poly(ADP-ribose) polymerase (PARP) specific mouse monoclonal antibodies and anticaspase-3 polyclonal rabbit antibody were provided by BD PharMingen (San Diego, CA, USA). Goat anti-actin polyclonal IgG and bovine anti-goat IgG-horseradish peroxidase (HRP) secondary antibody were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA Replication-defective (E1 and E3 deleted) recombinant adenoviral vectors AdVEGFBax (encoding hemagglutinin (HA)-tagged human Bax-alpha under the control of the human VEGF promoter element), AdVEGFEGFP (encoding enhanced green fluorescent protein (EGFP) under the control of the VEGF promoter element) and AdCMVEGFP (encoding EGFP under the control of the human cytomegalovirus (CMV) promoter element) were described previously. 9 Recombinant adenoviruses were propagated in 293 cells, purified by ultracenrifugation in a cesium chloride gradient, and subjected to dialysis. Viral titer was measured by a standard plaque assay using 293 cells and by absorbance of the dissociated virus at 260 nm.
EGFP assay
Cellular EGFP expression was quantitatively examined by FACS analysis and visualized using fluorescent microscopy. After AdVEGFEGFP infection, cells were collected at different time points and approximately 10 000 cells were illuminated at 488 nm and fluorescence was detected in the FITC (525/20 nm) channel. Nonspecific fluorescence was detected using a 575/30 nm emission filter in the propidium iodide (PI) channel. EGFP fluorescence is the mean fluorescence signal in EGFP-positive cells in relative units (ru) after subtraction of background fluorescence. An inverted system microscope Olympus IX70 (Olympus America, Melville, NY, USA) was used for initial screening of EGFP expression in cell culture.
Flow cytometry analysis
Annexin V, which preferentially binds to phosphatidylserine residues, and PI uptake were used for apoptosis evaluation. The exposure of phosphatidylserine on the outside of the plasma membrane is an early event characteristic of the apoptotic process, prior to the loss of integrity of the plasma membrane. Altered permeability of the plasma membrane of apoptotic cells enhances cellular uptake of PI. Combined staining with fluorescein-conjugated annexin V and PI distinguishes between early (annexin V positive and PI negative) and late apoptotic cells (annexin V-and PI-positive). 10 Cells were collected at different time points and double stained with FITC-conjugated annexin V and PI for 15 min at room temperature. Annexin V and PI were added according to the manufacturer's recommendations (BioVision, Palo Alto, CA, USA). Samples were immediately analyzed by FACScan. Annexin V and PI emissions were detected in the FL-1 (530/30 nm) and FL-2 (585/40 nm) channels, respectively. For each sample, data from approximately 10 000 cells were recorded in list mode on logarithmic scales. Analysis was performed with Cell Quest software (Becton Dickinson, San Jose, CA, USA) on cells characterized by forward/side scatter (FSC/SSC) parameters.
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Cell debris characterized by a low FSC/SSC was excluded from analysis. Annexin V-positive and PInegative cells were considered apoptotic, and cells taking only vital dye PI were considered necrotic. The percentages of apoptotic cells were calculated.
Cell viability assays
Cell viability was determined using the (3-(4,5-dimetilthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay according to the instructions of the manufacturer (Promega, Madison, WI, USA). Cell viability was also evaluated using trypan blue (Life Technologies, Grand Island, NY, USA) exclusion. Trypan blue-positive cells were considered dead, and percentage of dead cells was calculated among the total cell number (at least 200 cells). Cells were counted using a hemocytometer.
Caspase activity assay
Caspase-like activity was measured using Ac-DEVD-AFC, Ac-IETD-AFC and Ac-LEHD-AFC as fluorometric substrates for caspase-3, -8 and -9, respectively (BioVision). Cells were resuspended on ice in cell lysis buffer. The protein concentration in the samples was determined by the Biuret method using the BCA Protein Assay Kit (Pierce, Rockford, IL, USA). A measure of 50 mg of cell lysate was added to (1:1 v/v) 2 Â reaction buffer containing 10 mM DTT and AFC (7-amino-4-trifluoromethyl coumarin) conjugated substrates (50 mM final concentration) and incubated at 371C for 2 h. The optical density was measured in a VersaFluor fluorometer (Bio-Rad, Hercules, CA, USA) equipped with 400-nm excitation and 505-nm emission filters. Fold increase in caspase activity was determined by comparing relative fluorescence of treated samples with the level of the uninduced controls.
DNA fragmentation assay
At 48 h after infection, DNA was extracted using the Quick Apoptotic DNA Ladder Detection Kit according to the manufacturer's recommendations (BioVision), and after agarose gel electrophoresis DNA laddering was visualized by ethidium bromide staining.
Western blot analysis
The levels of DR5 protein expression, specific proteolysis of caspase-3, -8 and -9, and PARP were examined by Western blot technique. Actin protein expression was used as a loading control. Briefly, cells were collected, washed in Dulbecco's phosphate-buffered salt solution (DPBSS), and homogenized in ice cold lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 2 mM EDTA, 1% IGEPAL CA-630 (Sigma, St Louis, MO, USA). The cell homogenate was centrifuged at 14 000 g for 15 min at 41C. The protein concentration in the supernatant was determined by the Biuret method using the BCA Protein Assay Kit (Pierce). Each sample was denatured for 5 min at 1001C in loading buffer. Equal amounts of protein were loaded for each sample in all lanes and electrophoretically separated on 10 or 12% SDS-PAGE followed by transfer to a polyvinylidene difluoride (PVDF) membrane (Millipore, Bedford, MA, USA). The membrane was blocked with 5% non-fat milk (Bio-Rad) in TBS (135 mM NaCl, 2.5 mM KCl, 25 mM Tris-HCl, pH 7.5). Specific and secondary antibodies were used according to the manufacturer's recommendations. The membranes were processed and treated with HRP color development reagent (Bio-Rad).
Measurement of VEGF protein in cell culture supernatant
For generation of conditioned media after overnight incubation, cells were washed with DPBSS, and serumfree medium was added. Cell culture supernatant aliquots were collected after 18 h of normoxic incubation, centrifuged to remove floating cells, and stored at À201C. VEGF concentrations were assessed by using quantitative enzyme linked immunosorbent assay (ELISA) (R&D Systems, Minneapolis, MN, USA) following the manufacturer's instructions. The raw VEGF data were normalized according to the number of viable cells in each sample, as determined by using trypan blue (Life Technologies) exclusion as described above.
Caspase inhibition assay U373MG cells were incubated with 100 ng/ml TRA-8, infected with 100 MOI (multiplicity of infection) AdVEGFBax alone, or subjected to combined treatment for 96 h in the presence of 250 nM Z-DEVD-FMK, Z-IETD-FMK, Z-LEHD-FMK or Z-VAD-FMK caspase inhibitors diluted in dimethyl sulfoxide (DMSO) (BioVision) or DMSO (control). Cell viability after treatment was determined using the MTS assay as described above.
Animal studies
Female athymic nude mice 9-10 weeks old were purchased from the National Cancer Institute Frederick Cancer Research and Development Center (Frederick, MD, USA). U251MG cells were mixed (1:1) with Matrigel (Collaborative Biomedical Products, Bedford, MA, USA), and 2 Â 10 7 cells were injected subcutaneously (s.c.) into athymic nude mice. Treatment was started after 3 weeks at the time of established tumor growth (tumors were 6-8 mm in diameter). Animals were randomly divided into groups receiving different treatments: (1) 
Statistical analysis
All error terms are expressed as the standard deviation of the mean. Significance levels for comparison of differences between groups in the in vitro experiments were analyzed by the Student's t-test. The differences were considered significant when P-value was o0.05. All reported P-values are two-sided. In the animal model tumor therapy studies, the treatment groups were compared with respect to tumor size and percent of original tumor size over time, and complete tumor regressions. To test for significant differences in tumor Apoptosis in human glioma cell lines S Kaliberov et al size between treatment groups, one-way analysis of variance (ANOVA) test was conducted. When the ANOVA indicated that a significant difference existed (P-value o0.05), multiple comparison procedures were used to determine where the differences lay.
Results
Bax protein overexpression causes cancer cell death
We constructed the replication-defective recombinant adenoviral vector AdVEGFEGFP, which harbors the EGFP gene under the control of the human VEGF promoter sequence for determination of transduction efficiency and specificity of VEGF promoter-driven EGFP expression. Several glioma cell lines and normal human astrocytes were infected with 100 PFU per cell AdVEG-FEGFP or AdCMVEGFP. At 48 h after infection, cells were harvested and expression of EGFP was analyzed by FACS. As shown in Table 1 , human glioma cells demonstrated high levels of EGFP expression after infection with AdVEGFEGFP. For screening of relative sensitivity to adenoviral infection, these cell lines were infected with AdCMVEGFP, which harbors the EGFP gene under the control of the CMV promoter (Table 1) . These EGFP data correlated with VEGF expression in the human brain cell lines. The expression of the VEGF protein was examined using an ELISA of conditioned medium of cells grown under normoxic conditions and normalized according to the number of viable cells in each sample, as determined by using trypan blue exclusion (Table 1) . Glioma cell lines demonstrated high levels of VEGF protein secretion in comparison to normal human primary astrocytes under normoxic conditions.
For initial screening of the biological activity of recombinant Bax, we infected normal human primary astrocytes, D54MG, U87MG, U251MG and U373MG glioblastoma cells with AdVEGFBax (expressing Bax under the control of the VEGF promoter element) at various MOI (Figure 1a ). AdVEGFBax infection decreased the number of viable glioma cells, but not normal human astrocytes, as measured by MTS assay, at 72 h after infection. The relative sensitivity to AdVEGFBax infection for the glioma cell lines was U251MG4U373MG4U87MG4D54MG. To analyze the time course of cell death, we used the U251MG cell line, which was the most sensitive to AdVEGFBax infection. Cell death could be detected as early as 12 h after AdVEGFBax infection of U251MG glioma cells and affected nearly 90% of cells (for 50 MOI) within 48 h, as measured by trypan blue staining (Figure 1b) . To determine the expression of exogenous Bax in vitro, human glioma cells were infected with 100 MOI of AdVEGFBax. Equal amounts of infected and uninfected cell lysates were subjected to Western blotting analysis. The results showed that Bax overexpression (identified by anti-HA mouse monoclonal antibody) was present in AdVEGFBax-infected cells (Figure 1c ). There is no significant difference in the amounts of endogenous Bax protein (identified by anti-Bax mouse monoclonal antibody) in different glioma cell lines, detected by Western blotting analysis.
Susceptibility to TRA-8 is variable in different glioblastoma cell lines
To determine the cytotoxic activity of TRA-8 monoclonal antibody, several glioma cell lines and normal human astrocytes were treated with monoclonal antibody at different concentrations. The ability of TRA-8 to induce cytotoxicity in glioma cell lines was dose dependent (Figure 2a ), but the MTS assay did not show detectable changes of normal human astrocyte viability in the range 0-400 ng/ml (Figure 2a) , and TRA-8 at 1000 ng/ml still showed no cytotoxicity (data not shown). The susceptibility to cytotoxic effects of TRA-8 was variable in different glioma cell lines, for example, the range of concentration of monoclonal antibody to produce 50% viable cells (IC 50 ) was from 4.9 ng/ml for U373MG to 645.6 ng/ml for D54MG cells (Figure 2a ; data not shown). The relative sensitivity to TRA-8 treatment was U373MG4U87MG4U251MG4D54MG. Cell death could be detected as early as 1 h after incubation of U373MG glioma cells with TRA-8 and affected nearly 90% of cells (for 50 ng/ml) within 9 h, as measured by trypan blue staining (Figure 2b ). These data correlated with levels of DR5 protein expression in the human brain (Figure 1a and 2a) . In contrast, normal primary human astrocytes were resistant to TRA-8 and AdVEGFBax in vitro.
The purpose of the next study was to investigate whether increased cell death occurs in glioma cells following infection with AdVEGFBax in combination with TRA-8. For these experiments, we used U251MG The expression of DR5 and actin proteins was examined using a Western blotting analysis. Equal amounts of protein were loaded for each sample in all lanes and separated on SDS-PAGE followed by transfer to a PVDF membrane. One representative of three different experiments is shown.
Apoptosis in human glioma cell lines S Kaliberov et al and U373MG cell lines, which demonstrated opposite responses to TRA-8 treatment and AdVEGFBax infection, and D54MG cells, which were resistant to both treatments. As shown in Figure 3a , viability of U251MG cells was 71.1% following treatment with TRA-8 (100 ng/ ml) alone, 75.9% for AdVEGFBax (5 MOI) alone and 41.1% following their combined treatment as measured by MTS assay. Similar enhanced cell death results were obtained for U373MG and D54MG glioma cell lines (Figure 3b and c) . In contrast, there was no significant increased cell death observed after combined treatment with AdVEGFEGFP and TRA-8 antibody, and normal primary human astrocytes were resistant to TRA-8 treatment in the range 0-400 ng/ml after infection with 200 MOI AdVEGFBax (data not shown). Thus, the combination of TRA-8 treatment and overexpression of Bax can overcome TRA-8 resistance of glioma cells in vitro.
AdVEGFBax and TRA-8 treatment induces apoptosis in glioma cells
To confirm that AdVEGFBax and TRA-8 can induce apoptosis, D54MG cells were stained with both PI and FITC-labeled annexin V. Nontreated control cells were annexin V and PI negative. An increase in annexin V-positive cells was observed at 24-36 h compared to control cells after infection with AdVEGFBax ( Figure 3d 
Activation of caspases is involved in apoptosis of glioma cells lines
The caspase family of cysteine aspartyl-specific proteases play a key role in apoptosis regulation in mammalian cells. To confirm that activation of caspases is involved in apoptosis of glioblastoma cell lines after AdVEGFBax infection and TRA-8 treatment, proteolysis of caspase-3, -8 and -9 and PARP was evaluated by Western blot analysis of cellular proteins using antibodies against caspases that can detect both unprocessed proenzyme and active forms after cleavage. Data shown in Figure 4a demonstrate caspase-3, -8 and -9 activation and proteolysis of PARP in U373MG glioma cells after TRA-8 treatment and AdVEGFBax infection. Activation of caspases through specific cleavage resulted in internucleosomal DNA fragmentation ('DNA ladder') and PARP cleavage, which are hallmarks of apoptosis in mammalian cells. For the detection of DNA fragmentation, glioma cells were collected 48 h after infection, DNA was extracted and after agarose gel electrophoresis The activation of caspase-3, -8 and -9 after exposure of D54MG, U251MG and U373MG glioma cells to AdVEGFBax, TRA-8 or their combination was examined by proteolytic digestion of caspase-specific Ac-DEVD-AFC, Ac-IETD-AFC and Ac-LEHD-AFC fluorogenic substrates. There was a time-dependent increase in cleavage activity after AdVEGFBax or TRA-8 treatment. Caspaselike protease activation measured by DEVDase, IETDase and LEHDase activities was induced at 12-18 h following AdVEGFBax infection and remained elevated until 24 h; in contrast, enzyme activities were evident at 3-6 h, and increased amounts of caspases were detected at 12 h after TRA-8 exposure (data not shown). For subsequent experiments, TRA-8 antibody was added at 12 h following AdVEGFBax infection. As seen in Figure 4b -d, there was an increase in Ac-DEVD-AFC, Ac-IETD-AFC and Ac-LEHD-AFC cleavage activity in combination treatment as compared with single treatments. There was no AdVEGFEGFP-induced changes in caspase-like activity, in contrast to the case of AdVEGFBax treatment (data not shown). These data correlated with effects of increasing cell viability by using caspase inhibitors ( Figure 5 ). Figure 5 The caspase inhibitors protect U373MG cells against TRA-8-and Bax-mediated cell death. U373MG cells were preincubated for 1 h with 250 nM Z-DEVD-FMK, Z-IETD-FMK, Z-LEHD-FMK or Z-VAD-FMK caspase inhibitors or DMSO (control), followed by incubation with 10 ng/ ml TRA-8, infection with 100 MOI AdVEGFBax alone, or combined treatment for 96 h. Cell viability was determined by using the MTS assay. The values represent mean values7standard deviations of three independent experiments, each performed in 10 replicates.
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Exposure of U373MG glioma cells to DEVD-FMK, IETD-FMK, LEHD-FMK or VAD-FMK inhibited the enzymatic activity of caspase-3, -8, -9 and pan caspase, respectively, and decreased the cytotoxicity that was induced by TRA-8, AdVEGFBax treatment, or the combination of both treatments. Taken together, these data demonstrate that apoptosis induced by AdVEGFBax and TRA-8 antibody in glioma cells is dependent on the activation of the caspase pathway. These data indicate that the combination of TRA-8 treatment with specific overexpression of Bax using AdVEGFBax provided additive effects in glioma cells.
In vivo tumor therapy studies
To establish the efficacy of TRA-8, AdVEGFBax, and the combination of TRA-8 and AdVEGFBax treatment for U251MG tumors in vivo, subcutaneous U251MG xenografts were established in the flanks of athymic nude mice. Before treatment, the mean tumor sizes at baseline were not significantly different between treatment groups (P ¼ 0.69), and the within-treatment variances were not significantly different (P ¼ 0.21). The baseline mean and standard deviation for tumor sizes was 151754 mm Moreover, in the group treated with AdVEGFBax alone, five of the tumors underwent complete regression and three eventually recurred. In contrast, the group treated with TRA-8 in combination with AdVEGFBax showed 6/ 10 complete regressions without recurrence whereas TRA-8 in combination with AdVEGFEGFP produced 1/10 complete regressions. These data confirmed that tumor gene therapy using AdVEGFBax in combination with TRA-8 antibody resulted in tumor growth inhibition and complete tumor regression in 60% of the mice in comparison to less efficacy with TRA-8 alone or in combination with AdVEGFEGFP.
Discussion
Glioblastoma multiforme is the most common malignant brain tumor, which are highly vascularized and invasive neoplasms characterized by a high incidence of recurrence with a poor prognosis. The resistance to surgery, chemotherapy and radiation therapy is a significant obstacle to successful treatment. 11 Activation of apoptosis in glioma cells using overexpression of Bax protein may provide a promising approach for cancer gene therapy. A possible limitation of this strategy is the demand for tumor targeting and expression of the exogenous Bax gene, which restrict the clinical potential for this approach. One way to overcome this limitation is by utilizing a single adenoviral vector employing the Bax gene under the control of a tumor-specific and/or metabolically controlled promoter element. 12, 13 Neovascularization, the process leading to the formation of new blood vessels, plays a critical role in the growth of both primary and metastatic tumors.
14 The upregulation of angiogenesis is an essential event that accompanies glioma progression. Tumor angiogenesis is induced by the expression of angiogenic factors in tumors that stimulate host vascular endothelial cell mitogenesis and possibly chemotaxis. VEGF is a selective endothelial cell mitogen and angiogenic agent. Numerous growth factors and cytokines induce expression of VEGF. The elevated levels of expression of some oncogenes, such as ras, 15 raf, 16 src, 17 or mutant p53 18 can induce overexpression of VEGF in cancer cells. Some physiological conditions, for example, hypoxia or low pH, are characteristic of growing brain tumors which lead to upregulation of VEGF transcription in vivo.
19
Overexpression of VEGF has been demonstrated in cells from brain tumors. 20 Elevated VEGF expression has been reported to be a negative prognostic factor in patients with astrocytic tumors. 21 We have developed single adenoviral vectors employing EGFP or Bax genes under the control of the human VEGF promoter element. Our results demonstrated that high levels of VEGF expression TRA-8 is an anti-human DR5 monoclonal antibody, which can induce apoptosis of most TRAIL-sensitive tumor cells. TRA-8 triggers apoptosis and death of tumor cells by specific binding to DR5 receptors on the cell surface. 8 The results of this study show that glioma cells express elevated levels of DR5 protein in comparison with normal human astrocytes and are susceptible to TRA-8-induced apoptosis. TRA-8 monoclonal antibody induced rapid apoptosis and cell death in glioma cell lines, but did not produce detectable cytotoxicity of primary normal human astrocytes. The efficiency of TRA-8-induced apoptosis was variable in different malignant glioma cell lines. Glioma cells demonstrated p53-independent response to anti-DR5 monoclonal antibody treatment in contrast with AdVEGFBax infection. D54MG and U87MG (p53 wt) showed low levels of VEGF protein secretion in conditioned medium, EGFP expression and were resistant for AdVEGFBax infection, in comparison with U251MG and U373MG (p53 mut) cells. The basis for the variation in sensitivity of glioma cells to TRAIL-induced apoptosis is not clear, but there was no correlation between level of DR5 protein expression, as measured by Western blot analysis, and susceptibility to TRA-8 treatment. On the other hand, numerous mechanisms underlying regulation of TRAILinduced apoptosis have been described recently. It may be dependent on inactivation of DR5 receptor caused by mutations of DR5 gene in certain cancer cells 22 or expression of some intracellular regulators of the apoptosis signaling pathways. For example, c-FLIP protein has shown caspase-8-inhibitory activity. 23 Lower levels of caspase-8 activity lead to suppression of TRAILinduced apoptosis in brain tumors. 24, 25 Moreover, observations accumulated over the past decade show a close relationship between intrinsic and extrinsic apoptotic pathways. The findings that Bcl-X L and Bcl-2 overexpression or deficiency of Bax protein leads to TRAIL resistance suggest that these members of the Bcl-2 family are important factors for the regulation of TRAILmediated apoptosis. [26] [27] [28] Recently, the caspase-8-mediated activation of Bid was demonstrated. This activation of a member of the Bcl-2 family of proteins represents a mechanism for possible cross-interaction between the TNFR1/Fas death receptor and mitochondrial pathways of apoptosis. 29, 30 A recent publication by LeBlanc et al 31 demonstrated tumor cell resistance to TRAIL apoptosis through mutational inactivation of Bax. Bax-dependent release of mitochondrial Smac/DIABLO is an essential event that contributes to TRAIL-induced apoptosis of certain cancer cell lines. 32 In our experiments, AdVEGFBax-mediated overexpression of exogenous Bax protein induced apoptosis and cell death in glioma cell lines, through activation of both caspase-9 and -8. Activation of caspase-8 may reflect a possible Bax influence on TRAIL-mediated apoptosis signaling pathway. The mechanisms of increasing caspase-8 activity in response to Bax overexpression is still not clear. TRA-8 antibody, like TRAIL, can bind to DR5 and induces oligomerization of the receptor and recruitment of procaspase-8, which is proteolytically cleaved and thereby activated at the death-inducing signaling complex, which includes FADD, c-FLIP and procaspase-8 molecules. Activated caspase-8 leads to launching of the apoptosis executing caspase cascade. 5, 33, 34 Recently, inhibition of the cleavage step of procaspase-8 activation by ectopic expression of antiapoptotic proteins in the Bcl-2 family was shown. Possible explanations were that Bcl-2 and Bcl-X L proteins can block the activation of membrane-bound procaspase-8 or inhibit the recruitment of procaspase-8 to the TRAIL receptor. 27 On the other hand, Zhang et al 35 suggested that bifunctional apoptosis regulator (BAR) could mediate binding of procaspase-8 to mitochondria in a Bcl-2-regulated fashion. The binding of different forms of caspase-8 to complex mitochondrial BAR with Bcl-2 resulted in a decrease in caspase-8 activity in MCF7-Fas cells after apoptosis induction through CD95 (APO-1/Fas). 36 It is possible that signal diversification by heterodimerization of Bax with Bcl-2 is able to suppress caspase-8 and BAR complex formation, and thus increase the level of active caspase-8 with activation of the downstream apoptotic pathway. Thus, Bax overexpression may generate a more effective activation of TRAIL-induced apoptosis. Further functional characterization of the role of Bax in the extrinsic signaling pathway is required to understand the overall importance of this protein for regulation of apoptosis in cancer cells. The complexity of apoptosis, which can be produced through many different cell signaling pathways, and the fact that cancer cells can employ diverse mechanisms in varied circumstances to protect against it suggest that a combination of different approaches to induction of apoptosis in cancer cells will be more effective. In this study, the combination of TRA-8 treatment and specific overexpression of Bax protein using AdVEGFBax increased apoptosis and glioma cell death, through activation of caspase-8, -9 and -3.
The in vivo results indicated that TRA-8 monoclonal antibody alone or in combination with AdVEGFEGFP injection produced significant delay in U251MG human glioma tumor growth in comparison with PBS-treated controls. AdVEGFBax recombinant adenoviral injection as well as combined TRA-8 and AdVEGFBax treatment significantly inhibited the growth of U251MG tumors. Although there was no significant difference in mean tumor volumes, the combined TRA-8 and AdVEGFBax treatment produced the greatest number of complete regressions. The relative response of this tumor model correlated with what was observed in the in vitro proliferation and apoptosis assays with U251MG cells. Further work will be required to determine the optimal dose and administration schedule of AdVEGFBax in combination with TRA-8 antibody.
The results suggest that the combination of TRA-8 treatment with specific overexpression of Bax using AdVEGFBax produces an additive cytotoxic effect in glioma cells in vitro and in vivo. These data indicate that TRA-8 cancer therapy may be used either alone or in combination with Bax, which provides a promising potential for cancer therapy. Adenoviral-mediated specific overexpression of exogenous Bax can surmount Apoptosis in human glioma cell lines S Kaliberov et al resistance to TRA-8 in some glioma cell lines. In summary, these studies suggest that the combination of TRA-8 treatment with specific overexpression of Bax using AdVEGFBax may be an effective approach for the treatment of human malignant gliomas.
